At the time of writing, Seres Therapeutics Inc [MCRB] stock is trading at $14.85, up 18.14%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MCRB shares have gain 36.87% over the last week, with a monthly amount glided 84.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Seres Therapeutics Inc [NASDAQ: MCRB] stock has seen the most recent analyst activity on May 08, 2025, when Chardan Capital Markets downgraded its rating to a Neutral but kept the price target unchanged to $6 for it. Previously, JP Morgan downgraded its rating to Underweight on October 24, 2024. JP Morgan started tracking the stock assigning a Neutral rating and suggested a price target of $7 on April 21, 2023. Goldman downgraded its rating to a Sell and reduced its price target to $7 on July 23, 2021. In a note dated March 05, 2021, Chardan Capital Markets upgraded an Buy rating on this stock but restated the target price of $30.
For the past year, the stock price of Seres Therapeutics Inc fluctuated between $6.53 and $30.60. Currently, Wall Street analysts expect the stock to reach $1.25 within the next 12 months. Seres Therapeutics Inc [NASDAQ: MCRB] shares were valued at $14.85 at the most recent close of the market. An investor can expect a potential drop of -91.58% based on the average MCRB price forecast.
Analyzing the MCRB fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at 0.44, Equity is 266.73 and Total Capital is -0.88. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.77.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.63 points at the first support level, and at 10.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.53, and for the 2nd resistance point, it is at 18.20.
Ratios To Look Out For
It is important to note that Seres Therapeutics Inc [NASDAQ:MCRB] has a current ratio of 2.11. Further, the Quick Ratio stands at 2.11, while the Cash Ratio is 1.88.
Transactions by insiders
Recent insider trading involved Young Teresa L., that happened on May 16 ’25 when 63.0 shares were sold. CEO and President, Shaff Eric D. completed a deal on May 16 ’25 to sell 220.0 shares. Meanwhile, Chief Legal Officer and EVP DesRosier Thomas sold 79.0 shares on May 15 ’25.
